An open-label, randomized, phase II study had as the primary endpoint evaluation of the duration of grade 4 neutropenia after one cycle of toposide, methylprednisolone, cisplatin and cytarabine with the two different G-CSF strategies. Here, CSF3 is linked to neutropenia.